## Access & Reimbursement FOR ONPATTRO® (patisiran)



May 2022

Start Form

Reimbursement

Billing & Coding Overview

Billing & Coding Physician Office

Billing & Coding Hospital

Copay Claims

Example Order Set

Form

Start

Claims Copa

Example

Dosing

### Indication

ONPATTRO® (patisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

### **Important Safety Information**

### Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO. In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

### **Reduced Serum Vitamin A Levels and Recommended Supplementation**

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

### **Adverse Reactions**

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

#### For additional information about ONPATTRO, please see the accompanying full **Prescribing Information.**



### How Alnylam Assist<sup>™</sup> can help

After discussing ONPATTRO® (patisiran) with your patient, begin the enrollment process by completing the ONPATTRO Start Form. Upon receipt of the Start Form, an Alnylam Case Manager dedicated to your patient's needs will reach out to you and your patient within 2 business days.

### Your patient's Alnylam Case Manager will help with:



**Benefit verification** 



Education on the prior authorizations, claims, and appeals processes

Financial assistance program information for eligible patients<sup>a</sup>



Disease and product education

Guidance about product orders

Alnylam Field Reimbursement Directors (FRDs) are available to provide education about the ONPATTRO reimbursement process, including:

- ONPATTRO billing and coding requirements
- Chart documentation requirements
- Payer requirements

**Questions about how Alnylam Assist can help?** 

Talk to an Alnylam Case Manager 8AM-6PM ET, Monday-Friday at 1-833-256-2748.

<sup>a</sup>Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.



# Personalized support for patients throughout the treatment process



1 Complete Start Form



Alnylam Case Manager Reaches Out



3 Patient Assistance Offered

#### **Electronic Start Form**

Complete and submit the <u>electronic</u> <u>Start Form</u> online with your patient

#### **Downloadable Start Form**

OR \_\_\_\_\_

Print, complete with your patient, and fax the **<u>Start Form</u>** to 1-833-256-2747

### OR OR DocuSign Start Form

Begin the Start Form and send to your patient by email to complete via **DocuSign** 

- Disease and product education
- Insurance
  - Benefit verification and explanation
  - Coverage, coding, and reimbursement education
- Information on financial assistance for eligible patients<sup>a</sup>

Visit <u>www.AlnylamAssist.com</u> to complete the Start Form with your patient now, and to learn more about Alnylam Assist<sup>™</sup>.

<sup>a</sup>Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.



Alnylam Assist™

### Start Form

### Copay Claims

Dosing

### Support for your patients

### Alnylam Assist™ is here to help

Alnylam Assist will provide:

- An explanation of benefits so your patients understand their coverage
- Information about financial assistance programs for eligible patients<sup>a</sup>
- A **Patient Welcome Kit**, including educational materials designed to help patients understand ONPATTRO<sup>®</sup> (patisiran) and Alnylam Assist
- Education for your patients from a designated Alnylam Patient Education Liaison (PEL)
  - Regionally based Alnylam PELs are available to help patients gain a better understanding of the disease and treatment
  - PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice
- Support throughout treatment with ONPATTRO that is customized to each patient's communication preferences

<sup>a</sup>Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.



Claim Copa

Order Se Exampl

### Financial assistance programs

Financial assistance programs for eligible patients.<sup>a</sup> These may include:

- Alnylam Assist<sup>™</sup> Patient Assistance Program (PAP): Provides ONPATTRO<sup>®</sup> (patisiran) at no cost to eligible patients, primarily the uninsured, who meet specific financial criteria
- Alnylam Assist Commercial Copay Program<sup>b</sup>: Covers certain out-of-pocket costs for eligible patients with commercial insurance

### Eligibility criteria<sup>a</sup>

PAP	Commercial Copay
Primarily uninsured	Commercially insured patients <sup>b</sup>
Diagnosis of the polyneuropathy of hereditar	y transthyretin-mediated (hATTR) amyloidosis
US residency (inclu	ding US territories)
Financial eligibility requirements— supporting income documentation required <sup>c</sup>	Insurance must cover ONPATTRO

<sup>a</sup> Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

<sup>b</sup>Patients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist Commercial Copay Program. Out-of-pocket costs for the administration of ONPATTRO will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

<sup>c</sup>Acceptable forms of documentation may include: copy of most recent U.S. Individual Income Tax Return (IRS Form 1040); copy of most recent Social Security Benefit Statement (SSA-1099); copy of most recent pay stub.

> Once enrolled in Alnylam Assist, your patient's dedicated Alnylam Case Manager will review financial assistance programs your patient may qualify for based on their eligibility.



# How to complete the ONPATTRO<sup>®</sup> (patisiran) Start Form

This brochure will show you how to complete the Start Form. The notes on each page provide details to help ensure the form is filled out correctly. The Start Form serves as your patient's enrollment in Alnylam Assist<sup>™</sup> and requires the signature of both you and your patient, unless the patient is currently prescribed an Alnylam medicine and is enrolled in Alnylam Assist.

### It is important to note the following before submitting the Start Form:

- ▷ Ensure highlighted key areas are correctly filled out
- ▷ Confirm that you and your patient sign where indicated
- Make sure the Infusion Center Location information is provided for patients not receiving home infusions, if known

### **Options for getting started**

1. Complete and submit the electronic Start Form with your patient

----- OR ------

- 2. Complete the paper Start Form with your patient and fax to 1-833-256-2747
- 3. Begin the Start Form, filling in all details required from a healthcare professional, and then have your patient complete the form via **DocuSign**

OR -



All 3 options to get started can be found at www.AlnylamAssist.com.



For patients

#### Already Enrolled?

Patients currently prescribed an Alnylam medicine who are enrolled in Alnylam Assist™ through previous submission of a Start Form do not need to complete Sections 1 – 5.

#### Preferred Phone Number & Voicemail Checkbox

By allowing Alnylam Assist to leave voicemails, delays in benefit verification and other communications can be avoided.

#### Language Translation?

Alnylam Assist offers translation services for non– English-speaking patients.

#### **Insurance Information**

Patients (or their authorized representatives) can fill in the provided fields or attach copies of both sides of their insurance and pharmacy benefits cards.

<ul> <li>Before submitting the Start Form</li> <li>Patients currently prescribed a</li> </ul>					d to complete
Sections 1 - 5			-		
For Patients Alnylam Assist® Enrollment					
(Sections 1 – 5 to be read and co	mpleted by Patien	t or Patient's Au	thorized Repres	entativ	(e)
The purpose of this form is to permit Alnyla Pharmaceuticals, Inc., its affiliates, represe who have been prescribed an Alnylam mec nvestigating your insurance coverage, con your provider to fill your prescription; and four authorization in this form will relate to prescribed in the future.	m Assist® participants to re ntatives, agents, and contra licine. This includes: (1) pro irming out-of-pocket costs 3) providing you with disea	eceive additional inform actors ("Alnylam"). Alny oviding reimbursement , and reviewing eligibili use and medication-rela	nation and support ("P lam Assist® provides Pa and financial support ty for financial assistar ated educational resou	atient Sup atient Sup to eligible nce); (2) wo rces and c	port") from Alnylar port to eligible pat patients (such as orking with you and ommunications.
Please read this form carefully and ask	any questions that you r	nay have before signi	ing.		
1. Patient Information					
Name (First, MI, Last):					
Lawrence N. Reele					
Date of Birth: Month/Day/Year	Email:				
05/14/1956 Street Address:	LNReele@email.c	DM			
1020 Generic Ave.					
City:		State:	Zi	p:	
Springfield		MA	19	5123	
Preferred Phone Number: 10 Okay to leave voi (555)  37- 634	cemail	Alternative Phone	Number (if available): 🗌	Okay to lea	ve voicemail
Caregiver Name (optional):	Caregiver Relationship	to Patient (optional):	Caregiver Phone (opt	ional):	
Diane Reele	Wife		(555) 136-152	2	
Language translation? 📝 Yes, translation need	led 🗌 No If yes, please in	dicate language: Popetu	guese		
2. Insurance Information Attac	h a copy of both sides of yo	ur insurance card 🛛 🗆 C	heck if you do not have	insurance	
Primary Insurance Provider:	Employer Name:	Policy Number:		Group N	
ABC Insurance Co.	Company Inc.	12345678910		12-34	
Policyholder Name (First, MI, Last), if other than	the patient:	Policyholder Date	of Birth: Month/Day/Year		e Phone:  36-2222
Pharmacy Plan Provider (if applicable):	Policy Number:	Group Number:	Rx Bin Number:		Rx PCN Number:
Policyholder Name (First, MI, Last), if other than	the patient:	Policyholder Date	of Birth: Month/Day/Year	Insuranc	e Phone:
Secondary Insurance Provider (if applicable):	Employer Name:	Policy Number:		Group N	umber:
Policyholder Name (First, MI, Last), if other than	the patient:	Policyholder Date	of Birth: Month/Day/Year	Insuranc	e Phone:

Dosing



Order Se

### Authorization to share protected health information/authorization for Alnylam Assist™ enrollment

### Start Form



3. Authorization to Share Protected Health Information By signing below, I authorize my healthcare providers, including my physicians and pharmacies ("My Providers") and my health insurance plan ("My Plan") to share my medical information (such as information about my diagnosis, prescriptions, and treatment) and my insurance information ("My Information") with Alnylam so that Alnylam can provide Patient Support. I authorize My Providers to use My Information to provide me with certain offerings related to my treatment and any Alnylam medicine My Providers may prescribe for me at any time. I understand that my pharmacy will receive payment from Alnylam for disclosing My Information to Alnylam. I understand that once My Information has been disclosed, federal privacy laws may no longer protect the information. However, I understand that Alnylam agrees to protect My Information by using and disclosing it only for purposes described in this Authorization or as required by law. I understand that I may refuse to sign this Authorization, and that my treatment, insurance enrollment, and eligibility for insurance benefits are not conditioned upon signing this Authorization.

I also understand, however, that refusing to sign this Authorization means that I may not participate in Alnylam Assist® and may not be able to take advantage of other offerings by Alnylam. I may cancel or revoke this Authorization at any time by mailing a letter to Privacy Officer at Alnylam, Attn: Legal Department, 675 West Kendall Street, Cambridge, MA 02142 or by sending an email to privacy@alnylam.com.I understand that if I revoke this Authorization, My Providers and Alnylam will stop

using and sharing My Information under this Authorization, but my revocation will not affect uses and disclosures of My Information prior to my revocation in reliance upon this Authorization.

This Authorization expires ten (10) years from the date signed below, or earlier if required by state or local law, unless I revoke it before then. I understand that I may receive a copy of this Authorization.

Lawkence N. Keele	X James
Print Patient or Authorized Patient Representative Name	Signature of Patient or Authorized Patient Representative
	January 1, 2022
Relationship to Patient	Date
to provide me with Patient Support. I understand I agree that Alnylam may use My Information and with providing the Patient Support, administering by Alnylam to meet its legal obligations. For exam mail, phone, email, and/or text message) or my car related communications to my needs, and share Alnylam medicine to me. I understand that Alnyla	n the Alnylam Assist® program and authorize Alnylam d that Alnylam Assist® is an optional program. d share it with My Providers or My Plan in connection g the Alnylam Assist® program, or as otherwise required nple, Alnylam may communicate with me (such as by aregiver, use My Information to tailor the Alnylam Assist®-
Lawkence N. Reele	X James
Print Patient or Authorized Patient Representative Name	Signature of Patient or Authorized Patient Representative
	January, 1, 2022
Relationship to Patient	Date
	n Alnylam, to contact me by mail, email, fax, and/or telephone regarding marketing search surveys. I <b>understand that I am not required to provide this consent as</b>

#### Signature of Patient

The signature of the patient or authorized patient representative, with the date, is required **twice** on this page in Sections 3 and 4 unless the patient is currently prescribed an Alnylam medicine and is already enrolled in Alnylam Assist.

9

onpattro

### For healthcare providers/ prescriber declaration

#### **Infusion Center Location**

Ensure that infusion center information has been provided, if known. Please note that home infusion may also be an option.<sup>a</sup>

#### **Product Acquisition**

Select your preferred method of product acquisition (specialty pharmacy or specialty distributor). If acquisition method is unknown, select *Unknown*.

#### ONPATTRO<sup>®</sup> (patisiran) Dosing Information

Make sure to include the primary diagnosis code and patient's weight (kg).

#### **Signature of Prescriber**

- Confirm that your patient is being prescribed
   ONPATTRO as indicated by checking the box
- Ensure the prescriber's signature and date are included in Section 8

10

Name (First, Last): Charles Sample Practice Street Address: 530 Pioneer Road Zip: Phone:		Practice Name Sample Co	<u>.</u>		
Practice Street Address: 530 Pioneer Road			h		Specialty: Neurology
		I	City:	aton	State:
	Fax:	National Provi		State License	Number:
40520 (555) 876-5	5309	12345678	90	S943072	
Office Contact Name: Jane Smith		Phone: (555) 65	2-5678	Email: SampleDoc	Qemail.com
Infusion Center Location Name & Addi 202 Another Street	ress (if different from above):				irst Infusion Date:
Infusion Center Contact Name:		Phone:		Email:	e b, 2022
Richard I. Vaile Product Acquisition:		(555) 55	5-5055		
	ofamilial amyloidosis				
Dose: (Pincommended doue is 0.3 mg/ng supplied ONPATTRO (patisiran) 2 <b>B. Prescriber Declaration</b> By signing below, I certify that: > The information contained in t > I understand that Ainylam is no by Ainylam Assist <sup>®</sup> is education > Lunderstand that my patient n treatment or medical schools of	mgIV every 3 mgIV every 3 m this form is complete and accur ot responsible for filing claims on al in nature may authorize Alnylam Assist* t	rate to the best of my know or submitting other inform o provide Patient Support.	ation to my pati	at this program does n	he information provided ot include individual
ONPATTRO (patisiran) 2 8. Prescriber Declaration By signing below, I certify that: > The information contained in t > Understand that Alnylam is no by Alnylam Assist <sup>®</sup> is education by Alnylam Assist <sup>®</sup> is education > Lunderstand that my patient n treatment or medical advice to > Infurther certify that I understan or implied agreement or under prescribe ONPATTRO was, and	a as 10 mg/s mL vaids) mg IV every 3 n this form is complete and accur to tresponsible for filing claims is nal in nature may authorize Alnylam Assist <sup>®</sup> to the patient, and it does not re dn that any support provided b ristanding that i would recomm d in the future will be, based sol	rate to the best of my know or submitting other inform o provide Patient Support. place the medical treatme y Anylam Assist® on beha y Anylam Assist® on beha end, prescribe, or use ONR ely on my determination o	ation to my pati I understand th ent and care prov If of any patient ATTRO or any o f medical neces	ent's insurer and that the at this program does no rided by me as the pati is not made in exchang ther Annylam product, a sity	he information provided ot include individual ent's healthcare provider ge for any express and any decision to
ONPATTRO (patisiran) 2 8. Prescriber Declaration 3y signing below, I certify that: > The information contained in t > I understand that Alrylam is in by Alrylam Assist <sup>®</sup> is education > I understand that my patient n treatment or medical advice to > I further certify that I understar or implied agreement or under prescribe ONPATTRO was, and > I have obtained the required a treatment to Alrylam Assist <sup>®</sup>	m IV every 3 mg	ate to the best of my know or submitting other inform o provide Patient Support. place the medical treatme hend, prescribe, or use ONF ely on my determination o o ro release the referenced n	ation to my pati I understand th ent and care prov If of any patient PATTRO or any o If medical neces nedical and/or o	ent's insurer and that the this program does no indeed by me as the patient is not made in exchang ther Alnylam product, a sity ther patient information	he information provided ot include individual ent's healthcare provider ge for any express and any decision to
ONPATTRO (patisiran) 2 8. Prescriber Declaration 3y signing below, I certify that: > The information contained in It > I understand that Alnylam is no by Ainylam Assist <sup>1</sup> is education > I understand that my patient no treatment or medical advice to i further certify that I understan or implied agreement or under prescribe ONPATTRO was, and > I have obtained the required al treatment to Alnylam Assist <sup>1</sup> > Alnylam may convey on my be	d as 10 mg/5 mL vials) mg IV every 3 m this form is complete and accur ot responsible for filing claims of nal in nature nay authorize Alnylam Assist* to o the patient, and it does not re d that any support provided b srstanding that I would recomm in the future will be, based sol uthorizations from my patient I shalf the information described	weeks 2 ate to the best of my know or submitting other inform o provide Patient Support. place the medical treatme end, prescribe, or use OWP alyniam assist* on behal end or release the referenced m herein to be sent to a pha	ation to my pati I understand th ent and care prov If of any patient XATTRO or any o If medical neces nedical and/or o rmacy, if applica	ent's insurer and that the at this program does on vided by me as the pati is not made in exchang ther Alnylam product, a sity ther patient information uble	he information provided ot include individual ent's healthcare provider 6 for any express and any decision to n relating to my patient's
ONPATTRO (patisiran) 2 8. Prescriber Declaration By signing below, I certify that: > The information contained in t > I understand that Alrylam is in by Alrylam Assist <sup>®</sup> is education > I understand that my patient n treatment or medical advice to > I further certify that I understar or implied agreement or under prescribe ONPATTRO was, and > I have obtained the required a treatment to Alrylam Assist <sup>®</sup>	d as 10 mg/5 mL vials) mg IV every 3 m this form is complete and accur ot responsible for filing claims of nal in nature nay authorize Alnylam Assist* to o the patient, and it does not re d that any support provided b srstanding that I would recomm in the future will be, based sol uthorizations from my patient I shalf the information described	weeks 2 ate to the best of my know or submitting other inform o provide Patient Support. place the medical treatme end, prescribe, or use OWP alyniam assist* on behal end or release the referenced m herein to be sent to a pha	ation to my pati I understand th ent and care prov If of any patient XATTRO or any o If medical neces nedical and/or o rmacy, if applica	ent's insurer and that the at this program does on vided by me as the pati is not made in exchang ther Alnylam product, a sity ther patient information uble	he information provided ot include individual ent's healthcare provider 6 for any express and any decision to n relating to my patient's
ONPATTRO (patisiran) 2 8. Prescriber Declaration 3y signing below, I certify that: > The information contained in It > I understand that Alnylam is no by Ainylam Assist <sup>1</sup> is education > I understand that my patient no treatment or medical advice to i further certify that I understan or implied agreement or under prescribe ONPATTRO was, and > I have obtained the required al treatment to Alnylam Assist <sup>1</sup> > Alnylam may convey on my be	d as 10 mg/5 mL vials) mg IV every 3 m this form is complete and accur ot responsible for filing claims of nal in nature nay authorize Alnylam Assist* to o the patient, and it does not re d that any support provided b srstanding that I would recomm in the future will be, based sol uthorizations from my patient I shalf the information described	weeks 2 ate to the best of my know or submitting other inform o provide Patient Support. place the medical treatme end, prescribe, or use OWP alyniam assist* on behal end or release the referenced m herein to be sent to a pha	ation to my pati I understand th nt and care prov If of any patient ATTRO or any o f medical neces nedical and/or o rmacy, if applica	ent's insurer and that that is program does no vided by me as the pati is not made in exchang ther Alnylam product, a sity ther patient informatio able	he information provided ot include individual ent's healthcare provider 6 for any express and any decision to n relating to my patient's


<sup>a</sup>Home infusion may be an option for some patients. The decision for a patient to receive home infusion should be made after evaluation and recommendation by the treating physician and may not be covered by all insurance plans.

Please see Important Safety Information on page 2

and accompanying full **<u>Prescribing Information</u>**.




### **ONPATTRO®** (patisiran) Indication and Important Safety Information





### Once the completed Start Form is received by Alnylam Assist™



#### SETUP

#### 2. Alnylam Case Manager does benefit investigation

If a patient's insurance or site of care changes, a new benefit investigation must be done

#### **BENEFIT INVESTIGATION**

4. Alnylam Case Manager confirms copay affordability and site of care

5. Patient is "order ready"

#### **TREATMENT**<sup>d</sup>

6. Physician places order through specialty pharmacy or specialty distributor

3. Alnylam Case Manager relays results of benefit investigation to you and your patient during "Benefits Call Counsel" This includes information about prior authorization (if required)

IF REQUIRED

Prescribing physician submits prior authorization or works with identified specialty pharmacy to submit on their behalf

- It is the responsibility of the prescribing physician to submit the required documentation
- If the prior authorization is not approved, a resubmission or appeal may be required by the prescriber

Prior authorization is approved<sup>b,c</sup>

### Patient receives **ONPATTRO®** (patisiran) infusion and schedules next infusion

alf no infusion center has been identified, Alnylam Case Manager can do a search for infusion centers near the patient's preferred geographic location and confirm their in-/out-of-network status during the benefit investigation.

<sup>b</sup>If a reauthorization is required, a new request must be submitted.

Anylam Assist can provide education on prior authorization requirements and processes, but cannot guarantee that a patient's prior authorization will be approved.

<sup>a</sup>If your patient has a new prescribing physician, a new Start Form is required and the process must be repeated.



Order Se Example

Please see Important Safety Information on page 2 12 and accompanying full Prescribing Information.

Form Start

Copa

Medical chart documentation should be based on each patient's individual history, prior testing results, clinical condition, and actions actually performed by the clinician and other parties.

### **Examples of Authorization Documentation and Coverage Parameters**

Identify specific documentation that must be submitted with the request

prior authorization

coverage parameters

- Letter of medical necessity
- Chart notes
- Specific payer preauthorization/prior authorization form
- ONPATTRO<sup>®</sup> (patisiran) Prescribing Information
- Relevant literature, including published standards of care
- Clinical documentation related to the disease, which may include:
  - Rationale for treatment
  - Summary of patient's medical history
    - Diagnosis of hATTR amyloidosis
      - Documented transthyretin (TTR) variant, if known
      - Family history of hATTR amyloidosis, if known
    - Diagnosis of the polyneuropathy of hATTR amyloidosis
  - Peripheral sensory-motor neuropathy (describe patient's symptomatology, as appropriate: e.g., tingling or increased pain in the hands/feet, loss of feeling in the hands/feet, numbness or tingling in the wrists, carpal tunnel syndrome, loss of ability to sense temperature, difficulty with fine motor skills, weakness in the legs, difficulty walking) • Autonomic symptoms (describe patient's symptomatology, as appropriate:
    - e.g., orthostatic hypotension, abnormal sweating, sexual dysfunction, recurrent urinary tract infections, gastrointestinal (GI) manifestations [constipation and/or diarrhea, nausea, vomiting, anorexia, early satiety])
    - Baseline ambulatory status and/or Neuropathy Impairment Score (NIS) (see baseline assessments on following pages)
    - Results from tissue biopsy
    - Neurology consultation
    - Current supportive care management
    - Other relevant aspects of patient history, including imaging, studies, or assessments
- Determine the Time limits of authorization preauthorization/
  - Diagnosis limitations
  - Submission requirements

For your reference, you can find a sample letter of medical necessity under Forms & Documents on www.AlnylamAssist.com/HCP.



Order Se Example

# Ambulatory status assessments for hATTR amyloidosis

When documenting a patient's baseline ambulatory status, consider the following assessments. As a reminder, assessment of each patient's clinical condition should be based on the treating physician's professional judgment.

### Familial Amyloid Polyneuropathy (FAP) Stage

Clinical staging system as described by Coutinho et al,<sup>1</sup> according to sensory and motor neuropathy progression.

Stage	Description
Cì	<ul> <li>No symptoms of sensory or motor neuropathy</li> </ul>
Ŷ	• Unimpaired ambulation; mostly mild sensory and motor neuropathy in the lower limbs
Ŵ	<ul> <li>Assistance with ambulation required; mostly moderate impairment progression to the lower limbs, upper limbs, and trunk</li> </ul>
Ġ	• Wheelchair-bound or bedridden; severe sensory and motor neuropathy in all limbs

### Polyneuropathy Disability (PND) Score

Modified PND scoring system as described by Yamamoto et al<sup>2</sup> to assess the neuropathy of patients with hATTR amyloidosis.

Stage	Description	
Cî	• No symptoms of neuropathy	
Û	Sensory disturbances but preserved walking capability	
ŵ	<ul> <li>Impaired walking capacity but ability to walk without a stick or crutches</li> </ul>	
	• A: Walking with the help of one stick or crutch	
■■ ₩)	B: Walking with the help of two sticks or crutches	
K	Confined to a wheelchair or bedridden	




Example Order Se

# Neuropathy impairment assessment for hATTR amyloidosis

In addition to documenting ambulatory status, consider the following assessment for documenting a patient's sensory-motor neuropathy.

### **Neuropathy Impairment Score (NIS)**

Composite measure of motor and sensory neuropathy based on clinical assessment of lower and upper limbs, and cranial nerves<sup>3</sup>



### Domain items are scored as follows<sup>4</sup>:

Sensation: 0 (normal) to 2 (absent)

Reflexes: 0 (normal) to 2 (absent)

Motor strength and weakness: 0 (normal) to 4 (paralysis)



Dosing

### Coverage, coding, and payment

ONPATTRO<sup>®</sup> (patisiran) received US Food and Drug Administration (FDA) approval on August 10, 2018, and is indicated for the treatment of the polyneuropathy of hATTR amyloidosis in adults.

### Coverage

- For patients who are covered under Medicare Fee-for-Service, the Medicare Administrative Contractors (MACs) may require additional chart documentation to determine the medical necessity of ONPATTRO, although prior authorization is not required<sup>a,b</sup>
- For patients enrolled in a Medicaid or commercial health plan, ONPATTRO coverage will vary by payer<sup>a</sup>

#### Payment

Payer Type	Payment Methodology
Medicare Fee-for-Service	Average Sales Price (ASP) + 6%°
Medicare Advantage, Medicaid, and Commercial Payers	Payment rates will vary by payer and provider contract <sup>a</sup>

<sup>a</sup>It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for products and services rendered. Providers should contact third-party payers for specific information on their coding, coverage, and payment policies. <sup>b</sup>Medicare Advantage plans may require prior authorization for ONPATTRO.

<sup>c</sup>Does not account for any required payment reductions if sequestration is in effect.

Alnylam **Field Reimbursement Directors** are available to meet with you and your staff to answer reimbursement-related questions about ONPATTRO. Contact Alnylam Assist™ at 1-833-256-2748.



Dosing

### Physican office: coding

Please refer to the table below to support appropriate claims submission for ONPATTRO® (patisiran).

Code Type	Code	Code Description
ICD-10-CM	E85.1	Neuropathic heredofamilial amyloidosis
96365 CPT <sup>®a,b</sup> +96366 +96367	96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
	+96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour
	+96367	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour
J0222 J1100 J1200 J2780	J0222	Injection, patisiran, 0.1 mg
	J1100	Injection, dexamethasone sodium phosphate, 1 mg <sup>c</sup>
	J1200	Injection, diphenhydramine HCl, up to 50 mg <sup>c</sup>
	J2780	Injection, ranitidine HCl, 25 mg°
NDC <sup>d</sup>	10-digit: 71336-1000-1 11-digit: 71336-1000-01	10 mg/5 mL (2 mg/mL) single-dose vial

<sup>a</sup>CPT<sup>®</sup> 2021 Professional Edition. CPT is a registered trademark of the American Medical Association (AMA). <sup>b</sup>One-hour code covers up to 90 minutes.

<sup>c</sup>For premedications not available or not tolerated intravenously, equivalents may be administered orally.

<sup>d</sup>Given all the different possible sources for J1100, J1200, and J2780 NDCs as well as different HCPCS codes for premedications, please consult with an Alnylam Field Reimbursement Director or the manufacturers for the applicable NDC and HCPCS codes.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.



Dosing

### Physician office: sample CMS-1500 claim form

ONPATTRO<sup>®</sup> (patisiran) and the associated services provided in a physician office are billed on the CMS-1500 claim form or its electronic equivalent. A sample CMS-1500 claim form for billing ONPATTRO is provided on page 20.

- The sample CMS-1500 claim form for ONPATTRO is for illustrative purposes
- It is the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered
- Providers should contact payers for specific information on their coding, coverage, and payment policies
- Some payers may require the use of a JW modifier when billing for the unused portion of the single-dose vial (wastage)—providers should contact payers about specific coding and payment policies
- Providers should contact their billing software vendors to ensure that they are utilizing the recommended loops and segments

CMS=Centers for Medicare and Medicaid Services.



### Form Start

### Physician office: sample CMS-1500 claim form

### **Dosing calculation example**

- ONPATTRO<sup>®</sup> (patisiran) is supplied as a 10 mg/5 mL (2 mg/mL) solution in a single-dose vial
- The recommended dose of ONPATTRO is 0.3 mg/kg administered via intravenous (IV) infusion over ~80 minutes once every 3 weeks
- Dosing is based on actual body weight. For patients weighing  $\geq$ 100 kg, the recommended dose is 30 mg

### Calculation

How to calculate mg	How to calculate mL
(body weight [kg] x 0.3 mg/kg) = mg	(mg x 5 mL/10 mg) = mL

Proper preparation of ONPATTRO requires filtration to remove particulates. An additional vial may be required depending on the type of filter used and the amount of product that remains in the filter (hold-up volume). The dosing table found on page 38 assumes that 1 mL of drug product remains in the filter when determining the number of vials needed.

### Example - 68 kg patient

mg	mL
68 kg x 0.3 mg/kg = 20.4 mg	20.4 mg x 5 mL/10 mg = 10.2 mL

See dosing table on **page 36** for more detailed information on calculating dosage.



Exampl Order Se

### Physician office: sample CMS-1500 claim form Sample CMS-1500 Claim Form<sup>a</sup>

21
Enter the
appropriate primary
diagnosis code
from the patient's
medical record in
Locator 21A.

LOCATOR 21 ICD-IND

LOCATOR

Enter "0" to indicate use of ICD-10-CM diagnosis coding system.

### LOCATOR **24**<sub>A-B</sub>

Enter the date of service and the appropriate place of service code.

LOC	ATOR
24	
24	

Enter the HCPCS code J0222 on the first line, then the HCPCS codes for the premedications on lines 2-4, and the appropriate CPT code(s) on the following lines.

Confirm with the • payer whether additional information is required for each line

		INS			Έ C			M																				
APPRO					_	M COMM			2																		PICA	Ш
	EDICARE (edicare#)		/IEDIC/ /edical			RICARE	Г	CHAMF (Member	(N.C.1	GH (A	EQUP EALTH 24)	PLAN		EKA Majora		OTHER	1a. IN	ISUR	ED'S I.	D. NUI	MBEF	1			(For P	togram	n in Merri	1)
2 PAT	IENT'S NA	WE (L	ast Nar	ne, Ara	at Nam	e, Middle I	nitiai)	1	3.	PATIE	NTS B	іятн р 19	ATE		SEX		4. IN	JURE	D'S N/	WE (L	ast N	ame, F	irst Na	me, M	ddle In	nitial)		
5. PAT	ILE, LA IENT'S AC	DRES	7 <i>Cl</i> , 5 (No.,	N. Street	)				6.	<u>05</u> Patie	UT RE	LATION	Ship	M K TO IN			7. IN	JURE	D'S AD	ORES	IS (N	, She	et)					
	20 Ger	1eric	Ave							Self		ouse	Chi		Oth	3f 🗌												
сяту Spł	eingfiel	d						ST ATE MA	8.	RESE	AVED I	FOR NU	JCC U	SE			CITY										STATE	
ZIPCO	DDE					ONE (Inclu		Code)	1								ZIP C	ODE				Т	ELEPY	IONE	Include	e Area	Code)	
151; 9. OT		RED'S	NAME			: ) 37-  First Name		nital)	10	IS PA	TIENT	SCON		NREL	ATED	0	11.15	ISUR	ED'S F	OLICY	GRO	XUP OF	(	A NUM	) IREB			
a. OTH	IER INSUR	RED'S	POLIC'	YORG	ROUP	P NUMBER	1		a.	EMPL	_	VIT? (CU YES		r Prev Y_N			a. INI	BURE	D'SD/		BIR	ΓH Υ		мГ	- 7	SEX	F	
b. RES	BERVED F	OR NU	CC US	E					h.	AUTO	ACCIE	ENT?	l	_	PLAC	E (State)	b. 0	THER	i CLAIN	i IID (D	esign	ated by	NUC		_			
c. BES	ERVED F	OBINU	CCUR	E					┥。	OTHE		VES	[	Ϋ́, Ν	°∟		C IN		NCE P	LAN N	AME	OR PR	loge	AM NA	ME			
									1		Ľ	YES	[	<u>γ.</u> N	0		0. 110		1021									
d, INS	URANCE	PLAN	IAME	OR PRI	OGRAJ	VI NAME			10	1. CLA	MCO	DES (D	esigna	ted by	NUCC	)	d. IS		RE ANC							9, 9a, s		
12. PA to p	TIENT'S C process this	R AUT s claim.	REA HORIZ I also r	D BAC ED PE equest	RSON Payme	FORM BE 'S SIGNAT intof gover	FORE CO TURE 1 au	MPLETP thorize th nefits eithe	e relea er to m	SIGN N ise of a yself o	G THE ny max to the	SFORA tical or i party w	f. other in ho acc	itorma: epts ad	ton ne Isignm	essary nt	p	ISURI	ED'S C	R AUT	HOR	IZED F	ERSC	NSS	IGNAT	UREI	authorize r supplie	tor
	SNED										DATE					Г		SIGN	ED									
14. DA MV		RREN	T ILLINI Y	ESS, II	JURY	, or PREG	NANCY (I		5. OTH	IER DA	TE	MN	1,0	10 1	YY		16. D	ATES		BNT UP	NABL	EŢØV	VORK	IN CU		r 000		y
17. N#	ME OF RE	FERR	ING PF	QUAL	R OR	OTHER S	OURCE	-	7a.		-		_			-		ROM OSPI	TALE	TION	DATE	S REL	ATED	TO TO CL	IBREN	IT SEF	IVICES	
10.15	DITIONAL	~ ~ ~			-	esignated			710. N	PI							F	ROM	DELA					то	RGES			
19. AL	UTIONAL	CLAIN	TINFO	man	UN (D	esignated	dy NOCC)										20.0	-	/ES	_	NO	1		\$ CH	HGES	\$		
21. DI	AGNOBIS	OR NA	TURE	OFILL	NESS	OR INJUR	Y Relate			ne beli	w (24	Ð I	CD Inc	ιÖ			22. R	EBUE	MISSI	ON		a	RIGIN	AL REF	. NO.			
A L	85.1	_		8.	_		_	C.						4	-	+	23. P	RICR	AUTH	ORIZA	TION	NUME	ER					
L L	0.47	(S) OF	0.000	J.		8		K.				ES, OR	i.		_	E		F										
сч. н. MM	From	:(a) UF YY	MM	To DD	YY	PLACE OF SERVICE	EMG	(Exp CPT/HC	plain U CPCS	nusual	Circur	nstance MODII	SUPP S) FIER	UES		GNOBIS	ę		 AGES		G. DAY OR UNIT	s en S Pr		D. JAL		REN	J. IDERING IDER ID.	,
01	24 ] ;	201	12 1	31	120	1.0	1 1	J02			1			1	1	E85.I	1			4	20							
U	27 1	20	12	21	120	11		302						1		605.1	1 1	¥.44	-	- 1	20	51	N	PI				
01	24 2	20	12	31	20	1		III	00							885.1	X	¥.44			IC.	)	N	PI				
01	24 3	20 I	12	31	120	11			200		1	- 1		1		E85.I	۲.	4.14		- 1			N	PI				
	aul	261	10	21	100	Lu					,						1			,	-	1						
01.1	24 1 2	20	12 1	31	i20			JZ:	180	1				1		885.1	I K	¥-¥¥	-		2		N	PI				
									_		1		_	1	1	_			1				N	PI				
	1	1	-		1	1					1			1	T				1	1			N	PI				
25. FE	DERALT	VX I.D.	NUMB	ER	S	SN EN	26. P	ATIENT'S	S ACO	лиис	NO.	27	ACCI	RT.A		MENT?		OTAL	. CHAF	IGE	Р	29. AN				30. Rs	vd.for NU	JCC Use
IN () (	SNATURE CLUDING Sertify that ply to this I	DEGRI	ES OF	CREA	DENTI	ALS SR	32. 5	ERVICE	FACILI	TYL	CATIC		YE		NC		\$ 33. B	ILLIN	G PRC	MDEF	INFO	S D& PH	• (		)			1
αþ	e y io inis i	un and	weins	we a p																								
SIGNE	BD				DA	re	a.	N	IPI		b.						a.		NF	2	_	b.						
							w.nucc		_	- 2	_				TYPE	_				00.0	ACC	D OM	0.00	00.44	10 T F	20014-2	1700	(02.15

LOCATOR 24<sub>E</sub>

Specify the diagnosis, from Locator 21, that relates to the product or procedure listed in Locator 24D.

### LOCATOR 24<sub>6</sub>

Enter the number of service units for each line item. When billing J1100, report 10 units. When billing J1200,

report 1 unit. When billing J2780, report 2 units.

LOCATOR Enter the appropriate HCPCS code for ONPATTRO® (patisiran). 24<sub>D</sub> For Medicare, Medicaid, and Commercial Payers: J0222 - Injection, patisiran, 0.1 mg Enter the appropriate HCPCS code for premedications: J1100—Dexamethasone/Decadron J1200—Diphenhydramine/Benadryl J2780—Ranitidine/Zantac Shaded area of Locator 24D: N471336100001 XmL

<sup>a</sup>The codes listed on this sample claim form are for illustrative purposes only. It is the provider's responsibility to submit true and correct claims for products and services rendered.



### Form Start

### Claims Copa

Dosing

### Clean claim filing checklist

 $\bigotimes \bigotimes \bigotimes \bigotimes \bigotimes \bigotimes$ 

Select the appropriate primary diagnosis

Confirm appropriate clinical documentation to support diagnosis

Understand any payer-specific requirements (prior authorization, coding details, etc.)

Utilize all appropriate ICD-10, CPT<sup>®</sup>, and HCPCS codes

- In general, most payers will require the use of J0222 (Injection, patisiran, 0.1 mg) in the physician office setting
  - Remember: Billing unit = 0.1 mg
- Remember to use the sample claim form on page 20 as a guide

Anticipate requests from payers for additional clinical information prior to claims being processed for payment

It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for those products and services rendered. Contact third-party payers for those products and services rendered. Contact third-party payers for specific information on their coding and payment policies.



### Hospital outpatient: coding

Please refer to the table below to support appropriate claims submission for ONPATTRO® (patisiran).

Code Type	Code	Code Description
CD-10-CM	E85.1	Neuropathic heredofamilial amyloidosis
	96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
CPT <sup>®a,b</sup>	+96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour
	+96367	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour
	J0222	Injection, patisiran, 0.1 mg
LICDCCd	J1100	Injection, dexamethasone sodium phosphate, 1 mg <sup>c</sup>
HCPCS <sup>d</sup>	J1200	Injection, diphenhydramine HCl, up to 50 mg <sup>c</sup>
	J2780	Injection, ranitidine HCl, 25 mg <sup>c</sup>
	0250	General pharmacy
Revenue	0260	Intravenous therapy
	0636	Drugs requiring detailed coding
NDC <sup>d</sup>	10-digit: 71336-1000-1 11-digit: 71336-1000-01	10 mg/5 mL (2 mg/mL) single-dose vial

<sup>a</sup>CPT<sup>®</sup> 2021 Professional Edition. CPT is a registered trademark of the American Medical Association (AMA).

<sup>b</sup>One-hour code covers up to 90 minutes.

<sup>c</sup>For premedications not available or not tolerated intravenously, equivalents may be administered orally.

<sup>d</sup>Given all the different possible sources for J1100, J1200, and J2780 NDCs as well as different HCPCS codes for premedications, please consult with an Alnylam Field Reimbursement Director or the manufacturers for the applicable NDC and HCPCS code.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.



Copay Claims

Example Order Se

### Hospital outpatient: sample UB-04 claim form

ONPATTRO<sup>®</sup> (patisiran) and the associated services provided in a hospital outpatient setting are billed on the UB-04 claim form or its electronic equivalent. A sample UB-04 claim form for billing ONPATTRO is provided on page 26.

- The sample UB-04 claim form for ONPATTRO is for illustrative purposes
- It is the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered
- Providers should contact payers for specific information on their coding, coverage, and payment policies
- Some payers may require the use of a JW modifier when billing for the unused portion of the single-dose vial (wastage)—providers should contact payers about specific coding and payment policies
- Providers should contact their billing software vendors to ensure they are utilizing the recommended loops and segments



### Hospital outpatient: sample UB-04 claim form

### **Dosing calculation example**

- ONPATTRO<sup>®</sup> (patisiran) is supplied as a 10 mg/5 mL (2 mg/mL) solution in a single-dose vial
- The recommended dose of ONPATTRO is 0.3 mg/kg administered via intravenous (IV) infusion over ~80 minutes once every 3 weeks
- Dosing is based on actual body weight. For patients weighing  $\geq$ 100 kg, the recommended dose is 30 mg

### Calculation

How to calculate mg	How to calculate mL
(body weight [kg] x 0.3 mg/kg) = mg	(mg x 5 mL/10 mg) = mL

Proper preparation of ONPATTRO requires filtration to remove particulates. An additional vial may be required depending on the type of filter used and the amount of product that remains in the filter (hold-up volume). The dosing table found on page 38 assumes that 1 mL of drug product remains in the filter when determining the number of vials needed.

### Example - 68 kg patient

mg	mL
68 kg x 0.3 mg/kg = 20.4 mg	20.4 mg x 5 mL/10 mg = 10.2 mL

See dosing table on **page 36** for more detailed information on calculating dosage.



Order Se Exampl

### Start Form

### ling & Coding Hospital

Copay Claims

Dosing

### Hospital outpatient: sample UB-04 claim form

### LOCATOR 42

List the appropriate revenue code for the service provided.

For Medicare, use the revenue code 0636—Drugs requiring detailed coding.

For payers other than Medicare, the revenue code for ONPATTRO® (patisiran) may vary, although some **commercial** and **Medicaid** plans accept revenue code 0250—General pharmacy.




Enter the corresponding description for the revenue code listed in Locator 42.

### LOCATOR

Enter the appropriate HCPCS code: J0222—Injection, patisiran, 0.1 mg.

### Sample UB-04 Claim Form<sup>a</sup>



locator 40

Enter the HCPCS code J0222 on the first line, then the HCPCS codes for the premedications on lines 2-4, and the appropriate CPT code(s) on the following lines.

 Confirm with the payer whether additional information is required for each line

### **LOCATOR** 45

Enter the service date.

### locator 46

Enter the number of service units for each line item.

When billing J1100, report 10 units. When billing J1200, report 1 unit. When billing J2780, report 2 units.

### locator 47

Enter the total charge for each line item. Please note that the total charge for medications may vary.

#### **LOCATOR** 66

Enter "0" to indicate use of the ICD-10-CM diagnosis coding system.

<sup>a</sup>The codes listed on this sample claim form are for illustrative purposes only. It is the provider's responsibility to submit true and correct claims for products and services rendered.



### Form Start

### Claims Copa

Dosing

### Clean claim filing checklist

✓✓

Select the appropriate primary diagnosis

Confirm appropriate clinical documentation to support diagnosis

Understand any payer-specific requirements (prior authorization, coding details, etc.)

Utilize all appropriate ICD-10, CPT<sup>®</sup>, HCPCS, and Revenue codes

- In general, commercial, Medicare, and Medicaid payers will require the use of J0222 (Injection, patisiran, 0.1 mg) in the Hospital Outpatient Department setting
  - Remember: Billing unit = 0.1 mg
- Remember to use the sample claim form on page 25 as a guide

Anticipate requests from payers for additional clinical information prior to claims being processed for payment

It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for those products and services rendered. Contact third-party payers for those products and services rendered. Contact third-party payers for specific information on their coding and payment policies.



### Start Form

Example Order Se

Dosing

# Alnylam Assist™ copay claim submission




The following outline will show you how to submit a medical benefits claim, pharmacy claim, or mail-in rebate for ONPATTRO<sup>®</sup> (patisiran) and related premedications. Before submitting a claim, please ensure the following:

- The patient is enrolled in Alnylam Assist (via the Start Form found at <u>www.AlnylamAssist.com</u>)
- The patient's benefits have been verified
- The patient has provided their medical benefit or pharmacy member number

Upon a patient's enrollment in the Commercial Copay Program, an Alnylam Case Manager will provide your practice with the patient's Payer ID, Group Number, and Member Number required to submit a copay claim.









## Start

Form

### Billing & Coding Hospital

## Order Se

## Dosing

### Example Order Set

Requires review and approval by clinician, pharmacy, and/or any required hospital committees prior to adopting or using any portion of this example order set. Content should be revised to reflect your hospital's treatment protocol and the specifics of the EMR system.

Key ☑ Required step □ Per clinical judgment

### **Prior authorization**<sup>a</sup>

Ensure prior authorization is obtained for infusions, if required

## Cycle 1, Day 1 (cycle length – 21 days)

### **Premedications**

(recommended premedications are in bold; for premedications not available or not tolerated intravenously, equivalents may be administered orally)

### **Corticosteroid** (select one):

- □ Dexamethasone 10 mg intravenous (IV) once at least 60 minutes prior to ONPATTRO® (patisiran) administration. NOT FOR IV PUSH. (EPIC: Starting when released)
- Dexamethasone 10 mg oral once at least 60 minutes prior to ONPATTRO administration. (EPIC: Starting when released)

 $\Box$  Equivalent substitution  $\_$ 

### Analgesic/antipyretic (select one):

- □ Acetaminophen 500 mg oral once at least 60 minutes prior to ONPATTRO. (EPIC: Starting when released)
- □ Equivalent substitution \_

### H1 antagonist (select one):

- □ Diphenhydramine 50 mg IV once at least 60 minutes prior to ONPATTRO. (EPIC: Starting when released)
- Diphenhydramine 50 mg oral once at least 60 minutes prior to ONPATTRO. (EPIC: Starting when released)

Equivalent substitution .

### H2 antagonist (select one):

- □ Ranitidine 50 mg IV once at least 60 minutes prior to ONPATTRO. (EPIC: Starting when released)
- □ Ranitidine 150 mg oral once at least 60 minutes prior to ONPATTRO. (EPIC: Starting when released)

### $\Box$ Equivalent substitution $\_$

<sup>a</sup>Not in product label.

Please see Important Safety Information on page 2 29 and accompanying full Prescribing Information.



Copay Claims

Order Set

- □ Sodium Chloride 0.9% IV at 100 mL/h. (This is a suggested initial rate and should not supersede any provider order.) (EPIC: Starting when released)
- Dextrose 5% and Sodium Chloride 0.45% IV at 100 mL/h. (This is a suggested initial rate and should not supersede any provider order.) (EPIC: Starting when released)
- $\Box$  No hydration required.

### Final check prior to ONPATTRO® (patisiran) administration<sup>a</sup>

Ensure licensed provider has entered "OK to proceed with treatment" order.

### Treatment with ONPATTRO

In the event of an infusion-related reaction (IRR), medical management should be instituted as clinically indicated.

#### **ONPATTRO**, total body weight should be used in dosing:

- □ Patient weight <100 kg: ONPATTRO 0.3 mg/kg in NS 200 mL administered via IV infusion over approximately 80 minutes, once. Give at initial infusion rate of approximately 1 mL/min for the first 15 minutes, then increase to approximately 3 mL/min for the remainder of the infusion. Use a dedicated line for ONPATTRO treatment with an infusion set containing a 1.2 micron polyethersulfone (PES) in-line infusion filter. Use infusion sets and lines that are di(2-ethylhexyl)phthalate-free (DEHP-free). (EPIC: Once, starting 1 hour after treatment start time<sup>b</sup>)
- □ Patient weight ≥100 kg: ONPATTRO 30 mg in NS 200 mL administered via IV infusion over approximately 80 minutes, once. Give at initial infusion rate of approximately 1 mL/min for the first 15 minutes, then increase to approximately 3 mL/min for the remainder of the infusion. Use a dedicated line for ONPATTRO treatment with an infusion set containing a 1.2 micron PES in-line infusion filter. Use infusion sets and lines that are DEHP-free. (EPIC: Once, starting 1 hour after treatment start time<sup>b</sup>)

### **Nursing orders**

#### **ONPATTRO** administration instructions:

- ☑ The duration of ONPATTRO infusion may be extended in the event of IRRs such as flushing, back pain, nausea, abdominal pain, dyspnea, and headache. If an IRR occurs, consider slowing or interrupting the ONPATTRO infusion and instituting medical management (e.g., corticosteroids or other symptomatic treatment) as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved.
- Administer ONPATTRO only through a free-flowing venous access line. Monitor the infusion site for possible infiltration during drug administration. Suspected extravasation should be managed according to standard practice for nonvesicants.
- Observe the patient during the ONPATTRO infusion and, if clinically indicated, following the infusion.
- ☑ After completion of the ONPATTRO infusion, flush the IV administration set with 0.9% Sodium Chloride Injection, USP to ensure that all ONPATTRO has been administered.

<sup>a</sup>Not in product label.

<sup>b</sup>Treatment start time is the time of first premedication administration.

Please see Important Safety Information on page 2 and accompanying full Prescribing Information. 30



### Start Form

### Copay Claims

### **Clinical monitoring**

□ Monitor patient for signs of IRRs which may include, but are not limited to: arthralgia or pain (including back, neck, or musculoskeletal pain), flushing (including erythema of face or skin warm), nausea, abdominal pain, dyspnea or cough, chest discomfort or chest pain, syncope, headache, rash, chills, dizziness, fatique, increased heart rate or palpitations, hypotension, hypertension, and facial edema. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

### **Emergency medications**<sup>a</sup>

If an IRR occurs, consider slowing or interrupting the ONPATTRO® (patisiran) infusion and instituting medical management (e.g., corticosteroids or other symptomatic treatment) as clinically indicated according to institution-specific guidelines.

### Supportive care (take-home prescription)

□ Vitamin A daily while on therapy (recommended daily value is 3,000 IU for men and 2,333 IU for women).

### Patient counseling<sup>a</sup>

- ☑ Inform patients about the signs and symptoms of IRRs during ONPATTRO treatment. Advise patients to contact their healthcare professional immediately if they experience signs and symptoms of IRRs.
- Inform patients that ONPATTRO treatment leads to a decrease in vitamin A levels measured in the serum. Instruct patients to take the recommended daily allowance of vitamin A.

<sup>a</sup>Not in product label.

### Cycle 2, Day 1 (cycle length – 21 days)

### **Premedications**

(recommended premedications are in bold; for premedications not available or not tolerated intravenously, equivalents may be administered orally)

#### **Corticosteroid** (select one):

- □ Dexamethasone 10 mg IV once at least 60 minutes prior to ONPATTRO administration. NOT FOR IV PUSH. (EPIC: Starting when released)
- Dexamethasone 10 mg oral once at least 60 minutes prior to ONPATTRO administration. (EPIC: Starting when released)

 $\Box$  Equivalent substitution \_



Start Form

Dosing

### For patients who are tolerating their ONPATTRO<sup>®</sup> (patisiran) infusions but experiencing adverse reactions related to dexamethasone, reduce dose by 2.5 mg increments (minimum dose = 5 mg):

- □ Dexamethasone 7.5 mg IV once at least 60 minutes prior to ONPATTRO administration. NOT FOR IV PUSH. (EPIC: Starting when released)
- □ Dexamethasone 7.5 mg oral once at least 60 minutes prior to ONPATTRO administration. (EPIC: Starting when released)
- □ Dexamethasone 5 mg IV once at least 60 minutes prior to ONPATTRO administration. NOT FOR IV PUSH. (EPIC: Starting when released)
- □ Dexamethasone 5 mg oral once at least 60 minutes prior to ONPATTRO administration. (EPIC: Starting when released)
- $\Box$  Equivalent substitution \_

#### Analgesic/antipyretic (select one):

- □ Acetaminophen 500 mg oral once at least 60 minutes prior to ONPATTRO. (EPIC: Starting when released)
- Equivalent substitution \_\_\_\_\_

#### H1 antagonist (select one):

- □ Diphenhydramine 50 mg IV once at least 60 minutes prior to ONPATTRO. (EPIC: Starting when released)
- □ Diphenhydramine 50 mg oral once at least 60 minutes prior to ONPATTRO. (EPIC: Starting when released)
- Equivalent substitution \_\_\_\_\_

#### H2 antagonist (select one):

- □ Ranitidine 50 mg IV once at least 60 minutes prior to ONPATTRO. (EPIC: Starting when released)
- □ Ranitidine 150 mg oral once at least 60 minutes prior to ONPATTRO. (EPIC: Starting when released)
- Equivalent substitution \_\_\_\_\_

### Hydration<sup>a</sup>

- □ Sodium Chloride 0.9% IV at 100 mL/h. (This is a suggested initial rate and should not supersede any provider order.) (EPIC: Starting when released)
- □ Dextrose 5% Sodium Chloride 0.45% IV at 100 mL/h. (This is a suggested initial rate and should not supersede any provider order.) (EPIC: Starting when released)
- $\Box$  No hydration required.

### Final check prior to ONPATTRO administration<sup>a</sup>

□ Ensure licensed provider has entered "OK to proceed with treatment" order.

<sup>a</sup>Not in product label.



### Copay Claims

### Treatment with ONPATTRO® (patisiran)

In the event of an infusion-related reaction (IRR), medical management should be instituted as clinically indicated.

#### ONPATTRO, total body weight should be used in dosing:

- Patient weight <100 kg: ONPATTRO 0.3 mg/kg in NS 200 mL administered via IV infusion over approximately 80 minutes, once. Give at initial infusion rate of approximately 1 mL/min for the first 15 minutes, then increase to approximately 3 mL/min for the remainder of the infusion. Use a dedicated line for ONPATTRO treatment with an infusion set containing a 1.2 micron PES in-line infusion filter. Use infusion sets and lines that are DEHP-free. (EPIC: Once, starting 1 hour after treatment start time<sup>a</sup>)
- □ Patient weight ≥100 kg: ONPATTRO 30 mg in NS 200 mL administered via IV infusion over approximately 80 minutes, once. Give at initial infusion rate of approximately 1 mL/min for the first 15 minutes, then increase to approximately 3 mL/min for the remainder of the infusion. Use a dedicated line for ONPATTRO treatment with an infusion set containing a 1.2 micron PES in-line infusion filter. Use infusion sets and lines that are DEHP-free. (EPIC: Once, starting 1 hour after treatment start time<sup>a</sup>)

### **Nursing orders**

#### **ONPATTRO** administration instructions:

- ☑ The duration of ONPATTRO infusion may be extended in the event of IRRs such as flushing, back pain, nausea, abdominal pain, dyspnea, and headache. If an IRR occurs, consider slowing or interrupting the ONPATTRO infusion and instituting medical management (e.g., corticosteroids or other symptomatic treatment) as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved.
- Administer ONPATTRO only through a free-flowing venous access line. Monitor the infusion site for possible infiltration during drug administration. Suspected extravasation should be managed according to standard practice for nonvesicants.
- Observe the patient during the ONPATTRO infusion and, if clinically indicated, following the infusion.
- ☑ After completion of the ONPATTRO infusion, flush the intravenous administration set with 0.9% Sodium Chloride Injection, USP to ensure that all ONPATTRO has been administered.

### **Clinical monitoring**

□ Monitor patient for signs of IRRs which may include, but are not limited to: arthralgia or pain (including back, neck, or musculoskeletal pain), flushing (including erythema of face or skin warm), nausea, abdominal pain, dyspnea or cough, chest discomfort or chest pain, syncope, headache, rash, chills, dizziness, fatigue, increased heart rate or palpitations, hypotension, hypertension, and facial edema. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

<sup>a</sup>Treatment start time is the time of first premedication administration.



### Start Form

### **Emergency medications**<sup>a</sup>

☑ If an IRR occurs, consider slowing or interrupting the ONPATTRO<sup>®</sup> (patisiran) infusion and instituting medical management (e.g., corticosteroids or other symptomatic treatment) as clinically indicated according to institution-specific guidelines.

### Patient counseling<sup>a</sup>

- ☑ Inform patients about the signs and symptoms of IRRs during ONPATTRO treatment. Advise patients to contact their healthcare provider immediately if they experience signs and symptoms of IRRs.
- ☑ Inform patients that ONPATTRO treatment leads to a decrease in vitamin A levels measured in the serum. Instruct patients to take the recommended daily allowance of vitamin A.

<sup>a</sup>Not in product label.

### Cycle 3, Day 1 (cycle length – 21 days)

For subsequent cycles repeat Cycle 2.

To learn more about ONPATTRO visit **www.onpattrohcp.com**.



### Dosing guide



Use the table on the following page to calculate the dosage and number of vials needed for patients prescribed ONPATTRO<sup>®</sup> (patisiran), based on the recommended weight-based dosage

- ONPATTRO is supplied as a 10 mg/5 mL solution in a single-dose vial
- ONPATTRO is administered via IV infusion once every 3 weeks
- Dosing is based on actual body weight. For patients weighing <100 kg, the recommended dose is 0.3 mg/kg. For patients weighing ≥100 kg, the recommended dose is 30 mg

### **Premedications**<sup>5</sup>

All patients should receive premedication at least 60 minutes prior to ONPATTRO administration to reduce the risk of infusion-related reactions (IRRs).

Each of the following premedications should be given on the day of the infusion:

- IV corticosteroid (e.g., dexamethasone 10 mg, or equivalent)
- Oral acetaminophen (500 mg)
- IV H1 blocker (e.g., diphenhydramine 50 mg, or equivalent)
- IV H2 blocker (e.g., ranitidine 50 mg, or equivalent)

For premedications not available or not tolerated intravenously, equivalents may be administered orally.

For patients who are tolerating their ONPATTRO infusions but experiencing adverse reactions due to the corticosteroid premedication, the corticosteroid dose may be reduced by 2.5 mg increments to a minimum dose of 5 mg of dexamethasone (IV), or equivalent.

Some patients may require additional or higher doses of 1 or more of the premedications to reduce the risk of IRRs.



Proper preparation of ONPATTRO<sup>®</sup> (patisiran) requires filtration to remove particulates. An additional vial of ONPATTRO may be required depending on the type of filter used and the amount of product that remains in the filter (hold-up volume). The dosing table below assumes that 1 mL of drug product remains in the filter when determining the number of vials needed, based on the available manufacturer's information for the Pall PharmAssure<sup>®</sup> 0.45 micron 32 mm syringe filter with low protein binding Supor<sup>®</sup> membrane (Product ID 4644).

The **bold numbers** signify weights that may require an additional vial of ONPATTRO due to drug product remaining in the filter.

	25–4	9 kg			50–7	/4 kg		75–99 kg						
Body Weight (kg)	mg	mL	Vials	Body Weight (kg)	mg	mL	Vials		Body Veight (kg)	mg	mL	Vials		
25	7.5	3.75	1	50	15	7.5	2		75	22.5	11.25	3		
26	7.8	3.9	1	51	15.3	7.65	2		76	22.8	11.4	3		
27	8.1	4.05	2	52	15.6	7.8	2		77	23.1	11.55	3		
28	8.4	4.2	2	53	15.9	7.95	2		78	23.4	11.7	3		
29	8.7	4.35	2	54	16.2	8.1	2		79	23.7	11.85	3		
30	9	4.5	2	55	16.5	8.25	2		80	24	12	3		
31	9.3	4.65	2	56	16.8	8.4	2		81	24.3	12.15	3		
32	9.6	4.8	2	57	17.1	8.55	2		82	24.6	12.3	3		
33	9.9	4.95	2	58	17.4	8.7	2		83	24.9	12.45	3		
34	10.2	5.1	2	59	17.7	8.85	2		84	25.2	12.6	3		
35	10.5	5.25	2	60	18	9	2		85	25.5	12.75	3		
36	10.8	5.4	2	61	18.3	9.15	3		86	25.8	12.9	3		
37	11.1	5.55	2	62	18.6	9.3	3		87	26.1	13.05	3		
38	11.4	5.7	2	63	18.9	9.45	3		88	26.4	13.2	3		
39	11.7	5.85	2	64	19.2	9.6	3		89	26.7	13.35	3		
40	12	6	2	65	19.5	9.75	3		90	27	13.5	3		
41	12.3	6.15	2	66	19.8	9.9	3		91	27.3	13.65	3		
42	12.6	6.3	2	67	20.1	10.05	3		92	27.6	13.8	3		
43	12.9	6.45	2	68	20.4	10.2	3		93	27.9	13.95	3		
44	13.2	6.6	2	69	20.7	10.35	3		94	28.2	14.1	4		
45	13.5	6.75	2	70	21	10.5	3		95	28.5	14.25	4		
46	13.8	6.9	2	71	21.3	10.65	3		96	28.8	14.4	4		
47	14.1	7.05	2	72	21.6	10.8	3		97	29.1	14.55	4		
48	14.4	7.2	2	73	21.9	10.95	3		98	29.4	14.7	4		
49	14.7	7.35	2	74	22.2	11.1	3		99	29.7	14.85	4		

Billing & Coding Hospital

Copay Claims







8ам–6рм ЕТ, Monday–Friday ©: 1-833-256-2748 | ⊜: 1-833-256-2747

To learn more about ONPATTRO<sup>®</sup> (patisiran), visit <u>www.onpattrohcp.com</u>.

#### **References:**

1. Coutinho P, Martins da Silva A, Lopes Lima JL, et al. *Excerpta Medica*;1980:88-98. 2. Yamamoto S, Wilczek HE, Nowak G, et al. *Am J Transplant*. 2007;7(11):2597-2604. 3. Adams D, Suhr OB, Dyck PJ, et al. *BMC Neurol*. 2017;17(1):181. 4. Dyck PJ, Hughes RAC, O'Brien PC. In: Dyck PJ, Thomas PK, eds. *Peripheral Neuropathy*. 4th ed. Philadelphia, PA: Saunders; 2005:1031-1051. 5. ONPATTRO Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.

Please see <u>Important Safety Information</u> on page 2 and accompanying full <u>Prescribing Information</u>.





ONPATTRO, Alnylam Assist, and their associated logos are trademarks of Alnylam Pharmaceuticals, Inc. © 2022 Alnylam Pharmaceuticals, Inc. All rights reserved. TTR02-USA-00571-V4

#### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ONPATTRO<sup>®</sup> safely and effectively. See full prescribing information for ONPATTRO.

ONPATTRO (patisiran) lipid complex injection, for intravenous use

#### Initial U.S. Approval: 2018

-----DOSAGE AND ADMINISTRATION-----

- For patients weighing less than 100 kg, the recommended dosage is 0.3 mg/kg every 3 weeks by intravenous infusion. For patients weighing 100 kg or more, the recommended dosage is 30 mg (2.1)
- Premedicate with a corticosteroid, acetaminophen, and antihistamines (2.2)
- Filter and dilute prior to administration (2.3)
- Infuse over approximately 80 minutes (2.4)

-----DOSAGE FORMS AND STRENGTHS------Lipid Complex Injection: 10 mg/5 mL (2 mg/mL) in a single-dose vial (3)

#### -----CONTRAINDICATIONS------

#### None (4)

#### -----WARNINGS AND PRECAUTIONS------

- Infusion-related reactions: Monitor for signs and symptoms during infusion. Slow or interrupt the infusion if clinically indicated. Discontinue the infusion if a serious or life-threatening infusion-related reaction occurs (5.1)
- Reduced serum vitamin A levels and recommended supplementation: Supplement with the recommended daily allowance of vitamin A. Refer to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur (5.2)

#### -----ADVERSE REACTIONS------

The most frequently reported adverse reactions (that occurred in at least 10% of ONPATTRO-treated patients and at least 3% more frequently than on placebo) were upper respiratory tract infections and infusion-related reactions (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Alnylam Pharmaceuticals at 1-877-256-9526 or FDA at 1-800-FDA-1088 or <u>www.fda.gov/medwatch</u>.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 5/2021

#### FULL PRESCRIBING INFORMATION: CONTENTS\*

#### **1 INDICATIONS AND USAGE**

#### 2 DOSAGE AND ADMINISTRATION

- 2.1 Dosing Information
- 2.2 Required Premedication
- 2.3 Preparation Instructions
- 2.4 Infusion Instructions
- **3 DOSAGE FORMS AND STRENGTHS**
- **4 CONTRAINDICATIONS**

#### **5 WARNINGS AND PRECAUTIONS**

- 5.1 Infusion-Related Reactions
- 5.2 Reduced Serum Vitamin A Levels and Recommended Supplementation

#### **6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience
- 6.2 Immunogenicity
- 6.3 Postmarketing Experience

#### **8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation

- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment
- 8.7 Renal Impairment
- **11 DESCRIPTION**

#### 12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

#### 13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES
- 16 HOW SUPPLIED/STORAGE AND HANDLING
  - 16.1 How Supplied
  - 16.2 Storage and Handling

#### **17 PATIENT COUNSELING INFORMATION**

\*Sections or subsections omitted from the full prescribing information are not listed.

# FULL PRESCRIBING INFORMATION

# **1 INDICATIONS AND USAGE**

ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

# **2 DOSAGE AND ADMINISTRATION**

## 2.1 Dosing Information

ONPATTRO should be administered by a healthcare professional.

ONPATTRO is administered via intravenous (IV) infusion. Dosing is based on actual body weight.

For patients weighing less than 100 kg, the recommended dosage is 0.3 mg/kg once every 3 weeks.

For patients weighing 100 kg or more, the recommended dosage is 30 mg once every 3 weeks.

#### Missed Dose

If a dose is missed, administer ONPATTRO as soon as possible.

- If ONPATTRO is administered within 3 days of the missed dose, continue dosing according to the patient's original schedule.
- If ONPATTRO is administered more than 3 days after the missed dose, continue dosing every 3 weeks thereafter.

# 2.2 Required Premedication

All patients should receive premedication prior to ONPATTRO administration to reduce the risk of infusion-related reactions (IRRs) [see Warnings and Precautions (5.1)]. Each of the following premedications should be given on the day of ONPATTRO infusion at least 60 minutes prior to the start of infusion:

- Intravenous corticosteroid (e.g., dexamethasone 10 mg, or equivalent)
- Oral acetaminophen (500 mg)
- Intravenous H1 blocker (e.g., diphenhydramine 50 mg, or equivalent)
- Intravenous H2 blocker (e.g., ranitidine 50 mg, or equivalent)

For premedications not available or not tolerated intravenously, equivalents may be administered orally.

For patients who are tolerating their ONPATTRO infusions but experiencing adverse reactions related to the corticosteroid premedication, the corticosteroid may be reduced by 2.5 mg increments to a minimum dose of 5 mg of dexamethasone (intravenous), or equivalent.

Some patients may require additional or higher doses of one or more of the premedications to reduce the risk of IRRs [see Warnings and Precautions (5.1)].

## 2.3 Preparation Instructions

ONPATTRO must be filtered and diluted prior to intravenous infusion. The diluted solution for infusion should be prepared by a healthcare professional using aseptic technique as follows:

- Remove ONPATTRO from the refrigerator and allow to warm to room temperature. Do not shake or vortex.
- Inspect visually for particulate matter and discoloration. Do not use if discoloration or foreign particles are present. ONPATTRO is a white to off-white, opalescent, homogeneous solution. A white to off-white coating may be observed on the inner surface of the vial, typically at the liquid-headspace interface. Product quality is not impacted by presence of the white to off-white coating.
- Calculate the required dose of ONPATTRO based on the recommended weight-based dosage [see Dosage and Administration (2.1)].
- Withdraw the entire contents of one or more vials into a single sterile syringe.
- Filter ONPATTRO through a sterile 0.45 micron polyethersulfone (PES) syringe filter into a sterile container.
- Withdraw the required volume of filtered ONPATTRO from the sterile container using a sterile syringe.
- Dilute the required volume of filtered ONPATTRO into an infusion bag containing 0.9% Sodium Chloride Injection, USP for a total volume of 200 mL. Use infusion bags that are di(2-ethylhexyl)phthalate-free (DEHP-free).
- Gently invert the bag to mix the solution. Do not shake. Do not mix or dilute with other drugs.
- Discard any unused portion of ONPATTRO.
- ONPATTRO does not contain preservatives. The diluted solution should be administered immediately after preparation. If not used immediately, store in the infusion bag at room temperature (up to 30°C [86°F]) for up to 16 hours (including infusion time). Do not freeze.

## 2.4 Infusion Instructions

- Use a dedicated line with an infusion set containing a 1.2 micron polyethersulfone (PES) in-line infusion filter. Use infusion sets and lines that are DEHP-free.
- Infuse the diluted solution of ONPATTRO intravenously, via an ambulatory infusion pump, over approximately 80 minutes, at an initial infusion rate of approximately 1 mL/min for the first 15 minutes, then increase to approximately 3 mL/min for the remainder of the infusion. The duration of infusion may be extended in the event of an IRR [see Warnings and Precautions (5.1)].
- Administer only through a free-flowing venous access line. Monitor the infusion site for possible infiltration during drug administration. Suspected extravasation should be managed according to local standard practice for non-vesicants.
- Observe the patient during the infusion and, if clinically indicated, following the infusion [see Warnings and *Precautions (5.1)*].
- After completion of the infusion, flush the intravenous administration set with 0.9% Sodium Chloride Injection, USP to ensure that all ONPATTRO has been administered.

# **3 DOSAGE FORMS AND STRENGTHS**

Lipid Complex Injection: 10 mg/5 mL (2 mg/mL) white to off-white, opalescent, homogeneous solution in a single-dose vial.

# **4 CONTRAINDICATIONS**

None.

# **5 WARNINGS AND PRECAUTIONS**

# 5.1 Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO. In clinical studies, all patients received premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) to reduce the risk of IRRs. In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. Among ONPATTRO-treated patients who experienced an IRR, 79% experienced the first IRR within the first 2 infusions. The frequency of IRRs decreased over time. IRRs led to infusion interruption in 5% of patients. IRRs resulted in permanent discontinuation of ONPATTRO in less than 1% of patients in clinical studies. Across clinical studies, the most common symptoms (reported in greater than 2% of patients) of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache *[see Adverse Reactions (6.1)]*. Severe hypotension and syncope have been reported as symptoms of IRRs in the expanded access program and postmarketing setting.

Patients should receive premedications on the day of ONPATTRO infusion, at least 60 minutes prior to the start of infusion [see Dosage and Administration (2.2)]. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the ONPATTRO infusion and instituting medical management (e.g., corticosteroids or other symptomatic treatment), as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

Some patients who experience IRRs may benefit from a slower infusion rate or additional or higher doses of one or more of the premedications with subsequent infusions to reduce the risk of IRRs [see Dosage and Administration (2.2)].

# 5.2 Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance of vitamin A is advised for patients taking ONPATTRO. Higher doses than the recommended daily allowance of vitamin A should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

# **6 ADVERSE REACTIONS**

The following clinically significant adverse reactions are described elsewhere in the labeling:

• Infusion-Related Reactions [see Warnings and Precautions (5.1)]

## 6.1 Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of ONPATTRO cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

A total of 224 patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) received ONPATTRO in the placebo-controlled and open-label clinical studies, including 186 patients exposed for at least 1 year, 137 patients exposed for at least 2 years, and 52 patients exposed for at least 3 years. In the placebo-controlled study, 148 patients received ONPATTRO for up to 18 months (mean exposure 17.7 months). Baseline demographic and disease characteristics were generally similar between treatment groups. The median age of study patients was 62 years and 74% were male. Seventy-two percent of study patients were Caucasian, 23% were Asian, 2% were Black, and 2% were reported as other. At baseline, 46% of patients were in Stage 1 of the disease and 53% were in Stage 2. Forty-three percent of patients had Val30Met mutations in the transthyretin gene; the remaining patients had 38 other point mutations. Sixty-two percent of ONPATTRO-treated patients had non-Val30Met mutations, compared to 48% of the placebo-treated patients.

Upper respiratory tract infections and infusion-related reactions were the most common adverse reactions. One patient (0.7%) discontinued ONPATTRO because of an infusion-related reaction.

Table 1 lists the adverse reactions that occurred in at least 5% of patients in the ONPATTRO-treated group and that occurred at least 3% more frequently than in the placebo-treated group in the randomized controlled clinical trial.

# Table 1: Adverse Reactions from the Placebo-Controlled Trial that Occurred in at Least 5% of ONPATTRO-treated Patients and at Least 3% More Frequently than in Placebo-treated Patients

Adverse Reaction	ONPATTRO N=148 %	Placebo N=77 %	
Upper respiratory tract infections <sup>a</sup>	29	21	
Infusion-related reaction <sup>b</sup>	19	9	
Dyspepsia	8	4	
Dyspnea <sup>c, d</sup>	8	0	
Muscle spasms <sup>c</sup>	8	1	
Arthralgia <sup>c</sup>	7	0	
Erythema <sup>c</sup>	7	3	
Bronchitis <sup>e</sup>	7	3	
Vertigo	5	1	

<sup>a</sup> Includes nasopharyngitis, upper respiratory tract infection, respiratory tract infection, pharyngitis, rhinitis, sinusitis, viral upper respiratory tract infection, upper respiratory tract congestion.

<sup>b</sup> Infusion-related reaction symptoms include, but are not limited to: arthralgia or pain (including back, neck, or musculoskeletal pain), flushing (including erythema of face or skin warm), nausea, abdominal pain, dyspnea or cough, chest discomfort or chest pain, headache, rash, chills, dizziness, fatigue, increased heart rate or palpitations, hypotension, hypertension, facial edema.

<sup>c</sup> Not part of an infusion-related reaction.

<sup>d</sup> Includes dyspnea and exertional dyspnea.

<sup>e</sup> Includes bronchitis, bronchiolitis, bronchitis viral, lower respiratory tract infection, lung infection.

Four serious adverse reactions of atrioventricular (AV) heart block (2.7%) occurred in ONPATTRO-treated patients, including 3 cases of complete AV block. No serious adverse reactions of AV block were reported in placebo-treated patients.

Ocular adverse reactions that occurred in 5% or less of ONPATTRO-treated patients in the controlled clinical trial, but in at least 2% of ONPATTRO-treated patients, and more frequently than on placebo, include dry eye (5% vs. 3%), blurred vision (3% vs. 1%), and vitreous floaters (2% vs. 1%).

Extravasation was observed in less than 0.5% of infusions in clinical studies, including cases that were reported as serious. Signs and symptoms included phlebitis or thrombophlebitis, infusion or injection site swelling, dermatitis (subcutaneous inflammation), cellulitis, erythema or injection site redness, burning sensation, or injection site pain.

## 6.2 Immunogenicity

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. In addition, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ONPATTRO in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

Anti-drug antibodies to ONPATTRO were evaluated by measuring antibodies specific to PEG<sub>2000</sub>-C-DMG, a lipid component exposed on the surface of ONPATTRO. In the placebo-controlled and open-label clinical studies, 7 of 194 (3.6%) patients with hATTR amyloidosis developed anti-drug antibodies during treatment with ONPATTRO. One additional patient had pre-existing anti-drug antibodies. There was no evidence of an effect of anti-drug antibodies on clinical efficacy, safety, or the pharmacokinetic or pharmacodynamic profiles of ONPATTRO. Although these data do not demonstrate an impact of anti-drug antibody development on the efficacy or safety of ONPATTRO in these patients, the available data are too limited to make definitive conclusions.

## 6.3 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of ONPATTRO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Symptoms of infusion-related reactions have included syncope [see Warnings and Precautions (5.1)] and pruritus.

# **8 USE IN SPECIFIC POPULATIONS**

## 8.1 Pregnancy

## Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ONPATTRO during pregnancy. Physicians are encouraged to enroll pregnant patients, or pregnant women may register themselves in the program by calling 1-877-256-9526 or by contacting alnylampregnancyprogram@iqvia.com.

#### Risk Summary

There are no available data on ONPATTRO use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. ONPATTRO treatment leads to a decrease in serum vitamin A levels, and vitamin A supplementation is advised for patients taking ONPATTRO. Vitamin A is essential for normal embryofetal development;

however, excessive levels of vitamin A are associated with adverse developmental effects. The effects on the fetus of a reduction in maternal serum TTR caused by ONPATTRO and of vitamin A supplementation are unknown [see Clinical Pharmacology (12.2), Warnings and Precautions (5.2)].

In animal studies, intravenous administration of patisiran lipid complex (patisiran-LC) to pregnant rabbits resulted in developmental toxicity (embryofetal mortality and reduced fetal body weight) at doses that were also associated with maternal toxicity. No adverse developmental effects were observed when patisiran-LC or a rodent-specific (pharmacologically active) surrogate were administered to pregnant rats (see *Data*).

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.

#### Data

#### Animal Data

Intravenous administration of patisiran-LC (0, 0.15, 0.50, or 1.5 mg/kg) or a rodent-specific (pharmacologically active) surrogate (1.5 mg/kg) to female rats every week for two weeks prior to mating and continuing throughout organogenesis resulted in no adverse effects on fertility or embryofetal development.

Intravenous administration of patisiran-LC (0, 0.1, 0.3, or 0.6 mg/kg) to pregnant rabbits every week during the period of organogenesis produced no adverse effects on embryofetal development. In a separate study, patisiran-LC (0, 0.3, 1, or 2 mg/kg), administered to pregnant rabbits every week during the period of organogenesis, resulted in embryofetal mortality and reduced fetal body weight at the mid and high doses, which were associated with maternal toxicity.

Intravenous administration of patisiran-LC (0, 0.15, 0.50, or 1.5 mg/kg) or a rodent-specific surrogate (1.5 mg/kg) to pregnant rats every week throughout pregnancy and lactation resulted in no adverse developmental effects on the offspring.

## 8.2 Lactation

## Risk Summary

There is no information regarding the presence of ONPATTRO in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ONPATTRO and any potential adverse effects on the breastfed infant from ONPATTRO or from the underlying maternal condition.

In lactating rats, patisiran was not detected in milk; however, the lipid components (DLin-MC3-DMA and PEG<sub>2000</sub>-C-DMG) were present in milk.

## 8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

# 8.5 Geriatric Use

No dose adjustment is required in patients  $\geq$ 65 years old [see Clinical Pharmacology (12.3)]. A total of 62 patients  $\geq$ 65 years of age, including 9 patients  $\geq$ 75 years of age, received ONPATTRO in the placebo-controlled study. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

#### 8.6 Hepatic Impairment


## 8.7 Renal Impairment

No dose adjustment is necessary in patients with mild or moderate renal impairment (estimated glomerular filtration rate  $[eGFR] \ge 30$  to  $<90 \text{ mL/min}/1.73\text{m}^2$ ) [see Clinical Pharmacology (12.3)]. ONPATTRO has not been studied in patients with severe renal impairment or end-stage renal disease.

# **11 DESCRIPTION**

ONPATTRO contains patisiran, a double-stranded small interfering ribonucleic acid (siRNA), formulated as a lipid complex for delivery to hepatocytes. Patisiran specifically binds to a genetically conserved sequence in the 3' untranslated region (3'UTR) of mutant and wild-type transthyretin (TTR) messenger RNA (mRNA).

The structural formula is:



A, adenosine; C, cytidine; G, guanosine; U, uridine; Cm, 2'-O-methylcytidine; Um, 2'-O-methyluridine; dT, thymidine

ONPATTRO is supplied as a sterile, preservative-free, white to off-white, opalescent, homogeneous solution for intravenous infusion in a single-dose glass vial. Each 1 mL of solution contains 2 mg of patisiran (equivalent to 2.1 mg of patisiran sodium). Each 1 mL also contains 6.2 mg cholesterol USP, 13.0 mg (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino) butanoate (DLin-MC3-DMA), 3.3 mg 1,2-distearoyl-*sn*-glycero-3-phosphocholine (DSPC), 1.6 mg  $\alpha$ -(3'-{[1,2-di(myristyloxy)propanoxy] carbonylamino}propyl)- $\omega$ -methoxy, polyoxyethylene (PEG<sub>2000</sub>-C-DMG), 0.2 mg potassium phosphate monobasic anhydrous NF, 8.8 mg sodium chloride USP, 2.3 mg sodium phosphate dibasic heptahydrate USP, and Water for Injection USP. The pH is ~7.0.

The molecular formula of patisiran sodium is  $C_{412}$   $H_{480}$   $N_{148}$   $Na_{40}$   $O_{290}$   $P_{40}$  and the molecular weight is 14304 Da.

# **12 CLINICAL PHARMACOLOGY**

## 12.1 Mechanism of Action

Patisiran is a double-stranded siRNA that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.

## **12.2 Pharmacodynamics**

The pharmacodynamic effects of ONPATTRO were evaluated in hATTR amyloidosis patients treated with 0.3 mg/kg ONPATTRO via intravenous infusion once every 3 weeks.

Mean serum TTR was reduced by approximately 80% within 10 to 14 days after a single dose. With repeat dosing every 3 weeks, mean reductions of serum TTR after 9 and 18 months of treatment were 83% and 84%, respectively. The mean maximum reduction of serum TTR over 18 months was 88%. Similar TTR reductions were observed regardless of TTR mutation, sex, age, or race. In a dose-ranging study, greater TTR reduction was maintained over the dosing interval with the recommended dosing regimen of 0.3 mg/kg every 3 weeks compared to 0.3 mg/kg every 4 weeks.

Serum TTR is a carrier of retinol binding protein, which is involved in the transport of vitamin A in the blood. Mean reductions in serum retinol binding protein of 45% and serum vitamin A of 62% were observed over 18 months [see Warnings and Precautions (5.2)].

## **12.3 Pharmacokinetics**

Following a single intravenous administration, systemic exposure to patisiran increases in a linear and dose-proportional manner over the range of 0.01 to 0.5 mg/kg. Greater than 95% of patisiran in the circulation is associated with the lipid complex. At the recommended dosing regimen of 0.3 mg/kg every 3 weeks, steady state is reached by 24 weeks of treatment. The estimated mean  $\pm$  SD steady state peak concentrations ( $C_{max}$ ), trough concentrations ( $C_{trough}$ ), and area under the curve (AUC<sub> $\tau$ </sub>) were 7.15  $\pm$  2.14 µg/mL, 0.021  $\pm$  0.044 µg/mL, and 184  $\pm$  159 µg·h/mL, respectively. The accumulation of AUC<sub> $\tau$ </sub> was 3.2-fold at steady state, compared to the first dose. In the placebo-controlled study, interpatient variability in patisiran exposure did not result in differences in clinical efficacy (mNIS+7 change from baseline) or safety (adverse events, serious adverse events).

## Distribution

Plasma protein binding of ONPATTRO is low, with  $\leq 2.1\%$  binding observed *in vitro* with human serum albumin and human  $\alpha$ 1-acid glycoprotein. ONPATTRO distributes primarily to the liver. At the recommended dosing regimen of 0.3 mg/kg every 3 weeks, the mean  $\pm$  SD steady state volume of distribution of patisiran (V<sub>ss</sub>) was 0.26  $\pm$  0.20 L/kg.

#### **Elimination**

The terminal elimination half-life (mean  $\pm$  SD) of patisiran is 3.2  $\pm$  1.8 days. Patisiran is mainly cleared through metabolism, and the total body clearance (mean  $\pm$  SD) at steady state (CL<sub>ss</sub>) is 3.0  $\pm$  2.5 mL/h/kg.

## Metabolism

Patisiran is metabolized by nucleases to nucleotides of various lengths.

#### Excretion

Less than 1% of the administered dose of patisiran is excreted unchanged into urine.

#### Specific Populations

Age, race (non-Caucasian vs. Caucasian), and sex had no impact on the steady state pharmacokinetics of patisiran or TTR reduction. Population pharmacokinetic and pharmacodynamic analyses indicated no impact of mild or moderate renal impairment (eGFR  $\geq$ 30 to <90 mL/min/1.73m<sup>2</sup>) or mild hepatic impairment (bilirubin  $\leq$ 1 x ULN and AST >1 x ULN, or bilirubin >1.0 to 1.5 x ULN) on patisiran exposure or TTR reduction. ONPATTRO has not been studied in patients with severe renal impairment, end-stage renal disease, moderate or severe hepatic impairment, or in patients with prior liver transplant.

#### **Drug Interaction Studies**

No formal clinical drug interaction studies have been performed. The components of ONPATTRO are not inhibitors or inducers of cytochrome P450 enzymes or transporters at clinically relevant plasma concentrations. Patisiran is not a substrate of cytochrome P450 enzymes. In a population pharmacokinetic analysis, concomitant use of strong or moderate CYP3A inducers and inhibitors did not impact the pharmacokinetic parameters of patisiran. ONPATTRO is not expected to cause drug-drug interactions or to be affected by inhibitors or inducers of cytochrome P450 enzymes.

# **13 NONCLINICAL TOXICOLOGY**

## 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### Carcinogenesis

Patisiran-LC was not carcinogenic in TgRasH2 mice when administered at intravenous (IV) doses of 0, 0.5, 2, or 6 mg/kg every two weeks for 26 weeks.

#### **Mutagenesis**

Patisiran-LC was negative for genotoxicity in *in vitro* (bacterial mutagenicity assay, chromosomal aberration assay in human peripheral blood lymphocytes) and *in vivo* (mouse bone marrow micronucleus) assays.

#### Impairment of Fertility

Intravenous (IV) administration of patisiran-LC (0, 0.03, 0.1, or 0.3 mg/kg) or a rodent-specific (pharmacologically active) surrogate (0.1 mg/kg) to male rats every two weeks prior to and throughout mating to untreated females produced no adverse effects on fertility.

Intravenous administration of patisiran-LC (0, 0.15, 0.50, or 1.5 mg/kg) or a rodent-specific (pharmacologically active) surrogate (1.5 mg/kg) to female rats every week for two weeks prior to mating and continuing throughout organogenesis resulted in no adverse effects on fertility or on embryofetal development.

Intravenous administration of patisiran-LC (0, 0.3, 1, or 2 mg/kg) to adult monkeys every three weeks for 39 weeks produced no adverse effects on male reproductive organs or on sperm morphology or count.

# **14 CLINICAL STUDIES**

The efficacy of ONPATTRO was demonstrated in a randomized, double-blind, placebo-controlled, multicenter clinical trial in adult patients with polyneuropathy caused by hATTR amyloidosis (NCT 01960348). Patients were randomized in a 2:1 ratio to receive ONPATTRO 0.3 mg/kg (N=148) or placebo (N=77), respectively, via intravenous infusion once every 3 weeks for 18 months. All patients received premedication with a corticosteroid, acetaminophen, and H1 and H2 blockers. Ninety-three percent of ONPATTRO-treated patients and 62% of placebo-treated patients completed 18 months of the assigned treatment.

The primary efficacy endpoint was the change from baseline to Month 18 in the modified Neuropathy Impairment Score +7 (mNIS+7). The mNIS+7 is an objective assessment of neuropathy and comprises the NIS and Modified +7 (+7) composite scores. In the version of the mNIS+7 used in the trial, the NIS objectively measures deficits in cranial nerve function, muscle strength, and reflexes, and the +7 assesses postural blood pressure, quantitative sensory testing, and peripheral nerve electrophysiology. The maximum possible score was 304 points, with higher scores representing a greater severity of disease.

The clinical meaningfulness of effects on the mNIS+7 was assessed by the change from baseline to Month 18 in Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score. The Norfolk QoL-DN scale is a patient-reported assessment that evaluates the subjective experience of neuropathy in the following domains: physical functioning/large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The version of the Norfolk QoL-DN that was used in the trial had a total score range from -4 to 136, with higher scores representing greater impairment.

The changes from baseline to Month 18 on both the mNIS+7 and the Norfolk QoL-DN significantly favored ONPATTRO (Table 2, Figure 1 and Figure 3). The distributions of changes in mNIS+7 and Norfolk QoL-DN scores from baseline to Month 18 by percent of patients are shown in Figure 2 and Figure 4, respectively.

The changes from baseline to Month 18 in modified body mass index (mBMI) and gait speed (10-meter walk test) significantly favored ONPATTRO (Table 2).

Endpoint <sup>a</sup>	Baseline, Mean (SD)		Change from Baseline to Month 18, LS Mean (SEM)		ONPATTRO- Placebo Treatment	
	ONPATTRO N=148	Placebo N=77	ONPATTRO	Placebo	Difference, LS Mean (95% CI)	<i>p</i> -value
Primary						
mNIS+7 <sup>b</sup>	80.9 (41.5)	74.6 (37.0)	-6.0 (1.7)	28.0 (2.6)	-34.0 (-39.9, -28.1)	<i>p</i> <0.001
Secondary						
Norfolk QoL-DN <sup>b</sup>	59.6 (28.2)	55.5 (24.3)	-6.7 (1.8)	14.4 (2.7)	-21.1 (-27.2, -15.0)	<i>p</i> <0.001
10-meter walk test (m/sec) <sup>c</sup>	0.80 (0.40)	0.79 (0.32)	0.08 (0.02)	-0.24 (0.04)	0.31 (0.23, 0.39)	<i>p</i> <0.001
mBMI <sup>d</sup>	970 (210)	990 (214)	-3.7 (9.6)	-119 (14.5)	116 (82, 149)	<i>p</i> <0.001

## Table 2: Clinical Efficacy Results from the Placebo-Controlled Study


CI, confidence interval; LS, least squares; mBMI, modified body mass index; mNIS, modified Neuropathy Impairment Score; QoL-DN, Quality of Life – Diabetic Neuropathy; SD, standard deviation; SEM, standard error of the mean

<sup>a</sup> All endpoints analyzed using the mixed-effect model repeated measures (MMRM) method.

<sup>b</sup> A lower value indicates less impairment/fewer symptoms.

<sup>c</sup> A higher number indicates less disability/less impairment.


<sup>d</sup> mBMI: body mass index (BMI; kg/m<sup>2</sup>) multiplied by serum albumin (g/L); a higher number indicates better nutritional status.




#### Figure 1: Change from Baseline in mNIS+7

A decrease in mNIS+7 indicates improvement.

∆ indicates between-group treatment difference, shown as the LS mean difference (95% CI) for ONPATTRO – placebo.





mNIS+7 change scores are rounded to the nearest whole number; last available post-baseline scores were used. Categories are mutually exclusive; patients who died before 18 months are summarized in the "Death" category only.




Figure 3: Change from Baseline in Norfolk QoL-DN Score

A decrease in Norfolk QoL-DN score indicates improvement.

 $\Delta$  indicates between-group treatment difference, shown as the LS mean difference (95% CI) for ONPATTRO – placebo.




Figure 4: Histogram of Norfolk QoL-DN Change from Baseline at Month 18

Norfolk QoL-DN change scores are rounded to the nearest whole number; last available post-baseline scores were used. Categories are mutually exclusive; patients who died before 18 months are summarized in the "Death" category only.

Patients receiving ONPATTRO experienced similar improvements relative to placebo in mNIS+7 and Norfolk QoL-DN score across all subgroups including age, sex, race, region, NIS score, Val30Met mutation status, and disease stage.

# 16 HOW SUPPLIED/STORAGE AND HANDLING

## 16.1 How Supplied

ONPATTRO is a sterile, preservative-free, white to off-white, opalescent, homogeneous solution for intravenous infusion supplied as a 10 mg/5 mL (2 mg/mL) solution in a single-dose glass vial. The vial stopper is not made with natural rubber latex. ONPATTRO is available in cartons containing one single-dose vial each.

The NDC is: 71336-1000-1.

## 16.2 Storage and Handling

Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard vial if it has been frozen.

If refrigeration is not available, ONPATTRO can be stored at room temperature up to 25°C (up to 77°F) for up to 14 days.

For storage conditions of ONPATTRO after dilution in the infusion bag, see Dosage and Administration (2.3).

# **17 PATIENT COUNSELING INFORMATION**

#### Infusion-Related Reactions

Inform patients about the signs and symptoms of infusion-related reactions (e.g., flushing, dyspnea, chest pain, syncope, rash, increased heart rate, facial edema). Advise patients to contact their healthcare provider immediately if they experience signs and symptoms of infusion-related reactions [see Warnings and Precautions (5.1)].

#### Recommended Vitamin A Supplementation

Inform patients that ONPATTRO treatment leads to a decrease in vitamin A levels measured in the serum. Instruct patients to take the recommended daily allowance of vitamin A. Advise patients to contact their healthcare provider if they experience ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness) and refer them to an ophthalmologist if they develop these symptoms *[see Warnings and Precautions (5.2)]*.

#### Pregnancy

Instruct patients that if they are pregnant or plan to become pregnant while taking ONPATTRO they should inform their healthcare provider. Advise female patients of childbearing potential of the potential risk to the fetus. Encourage patients to enroll in the ONPATTRO pregnancy exposure registry if they become pregnant while taking ONPATTRO [see Use in Specific Populations (8.1)].

Manufactured for: Alnylam Pharmaceuticals, Inc. 300 Third Street, Cambridge, MA 02142 By: Ajinomoto Althea, Inc. 11040 Roselle Street, San Diego, CA 92121

ONPATTRO is a registered trademark of Alnylam Pharmaceuticals, Inc.